XML 97 R77.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Long-Term Investments (Details) - Schedule of Long-Term Investment - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2021
--- | --- | --- | ---
Non-marketable Cost Method Investments, net |  |  |
Non-marketable Cost Method Investments, net | $ 803,205 | $ 842,070 | $ 932,755
Equity Method Investments, net |  |  |
Equity Method Investments, net | 2,677,395 | 842,070 | 932,755
Braingenesis Biotechnology Co., Ltd. [Member] |  |  |
Non-marketable Cost Method Investments, net |  |  |
Non-marketable Cost Method Investments, net | 6,838 | 7,169 | 7,941
Genepharm Biotech Corporation [Member] |  |  |
Non-marketable Cost Method Investments, net |  |  |
Non-marketable Cost Method Investments, net | 20,876 | 21,887 | 24,244
BioHopeKing Corporation [Member] |  |  |
Non-marketable Cost Method Investments, net |  |  |
Non-marketable Cost Method Investments, net | 775,491 | 813,014 | 900,570
BioFirst Corporation [Member] |  |  |
Equity Method Investments, net |  |  |
Equity Method Investments, net | 1,874,190 |  |
Rgene Corporation [Member] |  |  |
Equity Method Investments, net |  |  |
Equity Method Investments, net |  |  |

X
- References No definition available. + Details
Name: | abvc_EquityMethodInvestmentsNetAbstract0
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_NonMarketableCostMethodInvestmentsNetAbstract0
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents the total non marketable cost method investments net included in earnings for the period as a result of selling marketable securities categorized as trading, available-for-sale, or held-to-maturity and any gains or losses realized during the period from the sale of investments accounted for under the cost method of accounting and/or investments that are separately or otherwise not categorized as trading, available-for-sale, or held-to-maturity. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities. + References No definition available. + Details
Name: | abvc_NonmarketableCostMethodInvestmentsNet
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |